在STAMPEDE 试验中随机分配接受多西他赛或阿比特龙治疗的前列腺癌男性的生活质量 Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. 摘要 《临床肿瘤学杂志(JCO)》在2022年发表了一篇关于多西他赛或阿比特龙治疗的前列腺癌男性的生活质量...
Rush HL, MurphyL, Morgans AK, et al. Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. J Clin Oncol. 2021 Nov 10;JCO2100728. doi: 10.1200/JCO.21.00728.
参考文献 [1]annoh L. Rush, et al. Comparative quality of life in patients randomized contemporaneously to docetaxel or abiraterone in the STAMPEDE trial. 2020 ASCO-GU. Oral presentation #GU20 [2]Sydes M, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer...
Androgen deprivation, docetaxel, stampede, zoledronic acidDespite the numerous regulatory approvals for prostate cancer, metastatic prostate cancer remains a huge burden for men worldwide. In an exciting development, James et al. recently published data from the Systemic Therapy in Advanced or ...
[4]mes ND, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. ...
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. 摘要 《临床肿瘤学杂志(JCO)》在2022年发表了一篇关于多西他赛或阿比特龙治疗的前列腺癌男性的生活质量的研究。由于...
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. 摘要 《临床肿瘤学杂志( JCO )》在2022年发表了一篇关于多西他赛或阿比特龙治疗的前列腺癌男性的生活质量的研究。由于多西他赛或醋酸阿比特龙联合泼尼松或泼尼松龙(AAP)在局部晚期或转移性...
In this latest data, we looked at this metastatic CSPC population, and the investigators went back in the docetaxel-treated arm and looked at that arm by high- and low-volume disease status. We remember that high- and low-volume disease was defined in the CHAARTED trial, with high-volume ...
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Lancet, 387 (2016), pp. 1163-1177 View PDFView articleView in ScopusGoogle Scholar ...
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPED... Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results ...